Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 203

1.

Talactoferrin alfa, a recombinant human lactoferrin promotes healing of diabetic neuropathic ulcers: a phase 1/2 clinical study.

Lyons TE, Miller MS, Serena T, Sheehan P, Lavery L, Kirsner RS, Armstrong DG, Reese A, Yankee EW, Veves A.

Am J Surg. 2007 Jan;193(1):49-54.

PMID:
17188087
2.

Talactoferrin stimulates wound healing with modulation of inflammation.

Engelmayer J, Blezinger P, Varadhachary A.

J Surg Res. 2008 Oct;149(2):278-86. doi: 10.1016/j.jss.2007.12.754. Epub 2008 Jan 10.

PMID:
18619616
3.

Intra-lesional injections of recombinant human epidermal growth factor promote granulation and healing in advanced diabetic foot ulcers: multicenter, randomised, placebo-controlled, double-blind study.

Fernández-Montequín JI, Valenzuela-Silva CM, Díaz OG, Savigne W, Sancho-Soutelo N, Rivero-Fernández F, Sánchez-Penton P, Morejón-Vega L, Artaza-Sanz H, García-Herrera A, González-Benavides C, Hernández-Cañete CM, Vázquez-Proenza A, Berlanga-Acosta J, López-Saura PA; Cuban Diabetic Foot Study Group.

Int Wound J. 2009 Dec;6(6):432-43. doi: 10.1111/j.1742-481X.2009.00641.x.

PMID:
20051095
4.

Randomized single-blind trial of topical ketanserin for healing acceleration of diabetic foot ulcers.

Martínez-de Jesús FR, Morales-Guzmán M, Castañeda M, Pérez-Morales A, García-Alonso J, Mendiola-Segura I.

Arch Med Res. 1997 Spring;28(1):95-9.

PMID:
9078595
5.

A phase 2 randomized, double-blind, placebo-controlled study of the safety and efficacy of talactoferrin in patients with severe sepsis.

Guntupalli K, Dean N, Morris PE, Bandi V, Margolis B, Rivers E, Levy M, Lodato RF, Ismail PM, Reese A, Schaumberg JP, Malik R, Dellinger RP; TLF LF-0801 Investigator Group.

Crit Care Med. 2013 Mar;41(3):706-16. doi: 10.1097/CCM.0b013e3182741551. Erratum in: Crit Care Med. 2014 May;42(5):e390. multiple investigator names added.

PMID:
23425819
6.

Effectiveness and safety of a novel gel dressing in the management of neuropathic leg ulcers in diabetic patients: a prospective double-blind randomized trial.

Abbruzzese L, Rizzo L, Fanelli G, Tedeschi A, Scatena A, Goretti C, Macchiarini S, Piaggesi A.

Int J Low Extrem Wounds. 2009 Sep;8(3):134-40. doi: 10.1177/1534734609344140.

PMID:
19703948
7.

Determinants and estimation of healing times in diabetic foot ulcers.

Zimny S, Schatz H, Pfohl M.

J Diabetes Complications. 2002 Sep-Oct;16(5):327-32.

PMID:
12200075
8.

The effect of short-contact topical tretinoin therapy for foot ulcers in patients with diabetes.

Tom WL, Peng DH, Allaei A, Hsu D, Hata TR.

Arch Dermatol. 2005 Nov;141(11):1373-7.

PMID:
16301384
9.

Treatment of chronic diabetic foot ulcers with bemiparin: a randomized, triple-blind, placebo-controlled, clinical trial.

Rullan M, Cerdà L, Frontera G, Masmiquel L, Llobera J.

Diabet Med. 2008 Sep;25(9):1090-5. doi: 10.1111/j.1464-5491.2008.02527.x. Erratum in: Diabet Med. 2008 Oct;25(10):1257.

PMID:
19183313
10.

The effects of ulcer size on the wound radius reductions and healing times in neuropathic diabetic foot ulcers.

Zimny S, Schatz H, Pfohl M.

Exp Clin Endocrinol Diabetes. 2004 Apr;112(4):191-4.

PMID:
15127323
11.

Recombinant human epidermal growth factor (REGEN-D 150): effect on healing of diabetic foot ulcers.

Mohan VK.

Diabetes Res Clin Pract. 2007 Dec;78(3):405-11. Epub 2007 Jul 25.

PMID:
17655964
12.

TGF-beta3 in the treatment of pressure ulcers: a preliminary report.

Hirshberg J, Coleman J, Marchant B, Rees RS.

Adv Skin Wound Care. 2001 Mar-Apr;14(2):91-5.

PMID:
11899912
13.

Prospective randomized controlled study of Hydrofiber dressing containing ionic silver or calcium alginate dressings in non-ischaemic diabetic foot ulcers.

Jude EB, Apelqvist J, Spraul M, Martini J; Silver Dressing Study Group.

Diabet Med. 2007 Mar;24(3):280-8.

PMID:
17305788
14.

Electric stimulation as an adjunct to heal diabetic foot ulcers: a randomized clinical trial.

Peters EJ, Lavery LA, Armstrong DG, Fleischli JG.

Arch Phys Med Rehabil. 2001 Jun;82(6):721-5.

PMID:
11387573
15.

Clinical efficacy of basic fibroblast growth factor (bFGF) for diabetic ulcer.

UCHI H, IGARASHI A, URABE K, KOGA T, NAKAYAMA J, KAWAMORI R, TAMAKI K, HIRAKATA H, OHURA T, FURUE M.

Eur J Dermatol. 2009 Sep-Oct;19(5):461-8. doi: 10.1684/ejd.2009.0750. Epub 2009 Jul 29.

PMID:
19638336
16.
17.

Effectiveness of recombinant human platelet-derived growth factor for the treatment of diabetic neuropathic foot ulcers.

Margolis DJ, Bartus C, Hoffstad O, Malay S, Berlin JA.

Wound Repair Regen. 2005 Nov-Dec;13(6):531-6.

PMID:
16283867
18.

Ultrasound therapy for recalcitrant diabetic foot ulcers: results of a randomized, double-blind, controlled, multicenter study.

Ennis WJ, Foremann P, Mozen N, Massey J, Conner-Kerr T, Meneses P.

Ostomy Wound Manage. 2005 Aug;51(8):24-39. Erratum in: Ostomy Wound Manage. 2005 Sep;51(9):14.

19.

Intralesional injections of Citoprot-P (recombinant human epidermal growth factor) in advanced diabetic foot ulcers with risk of amputation.

Fernández-Montequín JI, Infante-Cristiá E, Valenzuela-Silva C, Franco-Pérez N, Savigne-Gutierrez W, Artaza-Sanz H, Morejón-Vega L, González-Benavides C, Eliseo-Musenden O, García-Iglesias E, Berlanga-Acosta J, Silva-Rodríguez R, Betancourt BY, López-Saura PA; Cuban Citoprot-P Study Group.

Int Wound J. 2007 Dec;4(4):333-43. Epub 2007 Oct 22.

PMID:
17953679
20.

Treatment of nonhealing diabetic foot ulcers with a platelet-derived growth factor gene-activated matrix (GAM501): results of a phase 1/2 trial.

Mulder G, Tallis AJ, Marshall VT, Mozingo D, Phillips L, Pierce GF, Chandler LA, Sosnowski BK.

Wound Repair Regen. 2009 Nov-Dec;17(6):772-9. doi: 10.1111/j.1524-475X.2009.00541.x. Epub 2009 Oct 12.

PMID:
19821960

Supplemental Content

Support Center